Navigation Links
Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Date:2/27/2012

ease see attached prescribing information.  For additional information about INOMAX, please visit www.inomax.com

About Ikaria, Inc.
Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is investigating additional indications for INOMAX in bronchopulmonary dysplasia, and for inhaled nitric oxide with the INOpulse® DS drug-delivery system as a drug-device combination product in pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD). Ikaria's late-stage pipeline is also comprised of LUCASSIN® (terlipressin), a potential treatment for Hepatorenal Syndrome Type 1; as well as Bioabsorbable Cardiac Matrix (BCM), a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with a research facility in Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit www.ikaria.com.Company Contact:Media Contact:Samina Bari

Claire SojdaIkaria, Inc.

Tiberend Strategic Advisors, Inc.(908) 238-6372  

(212) 827-0020samina.bari@ikaria.com


SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Ikaria® to Present at 14th Annual BIO CEO & Investor Conference
2. Ikaria® to Present at 2011 BIO Investor Forum
3. Ikaria® To Present at 2011 BIO Business Forum and International Convention
4. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
5. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
6. Auxogyn Completes $20 Million In Series A Funding
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. MiMedx Group Completes $5,000,000 Private Placement
9. PDL BioPharma Completes Regular Quarterly Dividend Payment
10. CeNeRx BioPharma Completes $4.85 Million Financing
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... for its newly developed Bruton,s tyrosine kinase (BTK) ... completed. The results of these preclinical evaluations have ... Administration. The feedback received from the Agency is ... study. Additional preclinical work is required to begin ...
(Date:2/27/2015)... Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has ... Trypsin" report to their offering. , ... comprehensive data on Trypsin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
(Date:2/27/2015)... 27, 2015 The fully automated ... UC) can sequentially analyze up to 48 samples ... high-sensitivity detection of targets by mass spectrometry. ... fulfill the measurement requirements of a wide range ... drug delivery and search for disease biomarkers, additives ...
(Date:2/27/2015)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... that it will be presenting at CALBIO 2015 at ... at 3pm PST. Patrick Lucy, chief business officer of ... state of the biosimilar industry landscape entitled The ... more information on CALBIO 2015 and The Evolving ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Global Market Report of Trypsin 2014-2018 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... , ... Microbes that Produce Fuels Directly from Cellulosic Biomass , ... South San Francisco, CA (PRWEB) January 27, 2010 ... in the ability to make cellulosic-derived advanced biofuels. A collaborative team of researchers ...
... , CAMBRIDGE, Mass. ... The ALS Therapy Development Institute and Oxford BioMedica (LSE: OXB) ... of the first phase. The extended collaboration, which is funded ... of Oxford BioMedica,s preclinical gene therapy candidate, MoNuDin®, and to ...
... ... private companies providing paternity and other ancestry testing in Germany, summarizes ... German Genetic Diagnosis Act ("Gendiagnostikgesetz"): German legislation has passed several bills ... well as paternity testing. The new Genetic Diagnosis Act, which will ...
Cached Biology Technology:LS9, Inc., U.C Berkeley, and JBEI Make Major Breakthrough in Cellulosic Fuels Production 2LS9, Inc., U.C Berkeley, and JBEI Make Major Breakthrough in Cellulosic Fuels Production 3LS9, Inc., U.C Berkeley, and JBEI Make Major Breakthrough in Cellulosic Fuels Production 4ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 2ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 3ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 4ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis 5bj-diagnostik GmbH: The German Genetic Diagnosis Act will Become Effective 01.02.2010 - What Will Change for Paternity Testing? 2bj-diagnostik GmbH: The German Genetic Diagnosis Act will Become Effective 01.02.2010 - What Will Change for Paternity Testing? 3bj-diagnostik GmbH: The German Genetic Diagnosis Act will Become Effective 01.02.2010 - What Will Change for Paternity Testing? 4
(Date:2/9/2015)... 2015  Lintec of America recently announced an exclusive ... (CNT) macrostructures, including sheets, yarns and ribbons, developed at ... Leveraging the vast industrial resources of the global Lintec ... Lintec of America is forming the Nano-Science and Technology ... focusing on scaling up the manufacturing and commercialization of ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting its ... and has launched a new marketing campaign to solidify ... (CLO).  The new campaign focuses on First ... and shipments. The first headline in the ... Marken,s priorities with its client,s priorities. Marken recognizes the ...
(Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... University professor of physics and astronomy Apparao Rao has ... Fellows are elected by their peers for outstanding contributions ... one half of 1 percent of the membership. ... nanotubes and for elucidating the properties of carbon nanotubes ...
... PITTSBURGHUniversity of Pittsburgh researchers have developed the first ... finding that could help diminish the environmental and ... of the super-strong materials commonly used in products, ... team has found that carbon nanotubes deteriorate when ...
... 16, 2008) Researchers from Virginia Commonwealth University have identified ... and suppress a key protein that is overexpressed in 90 ... to an effective gene therapy for cancer. According ... the Department of Human and Molecular Genetics and director of ...
Cached Biology News:Pitt researchers create non-toxic clean-up method for potentially toxic nano materials 2Researchers identify new anti-tumor gene 2
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... The Flat Block Moto Alpha unit with ... a flat surface that is useful for microarrays ... of customized sample blocks. The sealing force of ... is actively measured to give repeatable results. This ...
... tubes are used to store 2.0 ml ... uniform walls for uniform heat transfer and ... caps. The O-rings are made of polyethylene ... from -55 to 150 degrees C. Supplied ...
... Tecan provides labware carriers to suit ... encountered in the life science laboratory. Labware ... on the worktable. Mounting is simple for ... system that ensures carriers are correctly guided ...
Biology Products: